CRISPR Therapeutics AG (CRSP)
60.83
+3.76
(+6.58%)
USD |
NASDAQ |
Aug 25, 16:00
60.58
-0.25
(-0.41%)
After-Hours: 19:32
CRISPR Therapeutics Total Assets (Quarterly) : 2.651B for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.651B |
| March 31, 2026 | 2.726B |
| December 31, 2025 | 2.265B |
| September 30, 2025 | 2.245B |
| June 30, 2025 | 2.030B |
| March 31, 2025 | 2.166B |
| December 31, 2024 | 2.242B |
| September 30, 2024 | 2.256B |
| June 30, 2024 | 2.340B |
| March 31, 2024 | 2.439B |
| December 31, 2023 | 2.230B |
| September 30, 2023 | 2.087B |
| June 30, 2023 | 2.197B |
| March 31, 2023 | 2.244B |
| December 31, 2022 | 2.243B |
| September 30, 2022 | 2.353B |
| June 30, 2022 | 2.463B |
| March 31, 2022 | 2.606B |
| December 31, 2021 | 2.752B |
| September 30, 2021 | 2.822B |
| June 30, 2021 | 2.900B |
| Date | Value |
|---|---|
| March 31, 2021 | 1.958B |
| December 31, 2020 | 1.828B |
| September 30, 2020 | 1.485B |
| June 30, 2020 | 1.047B |
| March 31, 2020 | 1.007B |
| December 31, 2019 | 1.067B |
| September 30, 2019 | 720.59M |
| June 30, 2019 | 494.24M |
| March 31, 2019 | 497.87M |
| December 31, 2018 | 489.02M |
| September 30, 2018 | 518.90M |
| June 30, 2018 | 353.13M |
| March 31, 2018 | 374.45M |
| December 31, 2017 | 271.35M |
| September 30, 2017 | 282.32M |
| June 30, 2017 | 304.98M |
| March 31, 2017 | 322.35M |
| December 31, 2016 | 344.96M |
| September 30, 2016 | 278.65M |
| June 30, 2016 | 293.06M |
| March 31, 2016 | 242.27M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 27.42B |
| BeOne Medicines Ltd. | 9.176B |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 186.45M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 904.22M |
| Shareholders Equity (Quarterly) | 1.747B |
| Debt to Equity Ratio | 0.4487 |
| Current Ratio | 17.85 |
| Net Debt Paydown Yield | -2.14% |